475654-43-4

Usage

Uses

Used in Pharmaceutical Synthesis:
6-chloro-5-methoxy-2,3-dihydro-1H-inden-1-one is used as a key intermediate in the pharmaceutical industry for the synthesis of various drugs. Its unique chemical structure allows for the development of new therapeutic agents with potential applications in treating a range of medical conditions.
Used in Agrochemical Synthesis:
In the agrochemical industry, 6-chloro-5-methoxy-2,3-dihydro-1H-inden-1-one is employed as a building block for the preparation of various agrochemicals. Its incorporation into these compounds can enhance their effectiveness in protecting crops from pests and diseases, thereby contributing to increased agricultural productivity.
Used in Organic Compound Preparation:
6-chloro-5-methoxy-2,3-dihydro-1H-inden-1-one is utilized as a versatile building block in the preparation of other organic compounds. Its chemical properties make it suitable for use in the synthesis of a wide range of organic molecules, which can be applied in various fields, including materials science, chemical engineering, and pharmaceuticals.
Used in Medicinal Chemistry Research:
Due to its potential biological activities, 6-chloro-5-methoxy-2,3-dihydro-1H-inden-1-one is of interest for medicinal chemistry research. Scientists are exploring its potential applications in the development of new drugs and therapeutic agents, as well as its role in understanding various biological processes and mechanisms.
Safety Considerations:
It is important to handle 6-chloro-5-methoxy-2,3-dihydro-1H-inden-1-one with care and follow proper safety procedures due to its potential hazards. This includes wearing appropriate personal protective equipment, working in a well-ventilated area, and adhering to established safety guidelines to minimize the risk of exposure and ensure the safety of researchers and workers in the field.

Upstream product

• 766-51-8 2-Chloroanisole 
• 625-36-5 2-chloropropionyl chloride 
• 5111-70-6 5-methoxy-1-indanone 
• 475654-41-2 trans-4-chloro-3-methoxycinnamic acid 
• 475654-42-3 3-(4-chloro-3-methoxy)phenyl-propanoic acid 
• 13726-16-4 4-chloro-3-methoxybenzaldehyde 

Downstream Products

• 475654-44-5 6-chloro-5-methoxy-1-phenyl-1H-indene 

Relevant academic research and scientific papers

Development of a phase transfer catalyzed asymmetric synthesis for an estrogen receptor beta selective agonist

A practical asymmetric synthesis of the estrogen receptor beta selective agonist (7β-9aβ)-1,4-dichloro-2-hydroxjgibba-1(10a)2,4,4b-tetraen-6- one (1), proceeding by way of six isolated intermediates and without recourse to chromatography, is described. Highlights of the process route developed are two chemoselective chlorinations, a lithiated hydrazone alkylation and an asymmetric Michael addition of indanone 11 to methyl vinyl ketone (using 15 mol % of cinchonine-derived catalyst 20g) to set the all-carbon quaternary asymmetric stereocenter. The challenges addressed in scaling the latter heterogeneous biphasic phase transfer reaction to 44 mol (14 kg) scale are discussed in detail. Overall, the chemistry developed has been used to prepare > 6 kg of drug candidate 1 in 18% overall yield and with >99% ee.

PROTEIN TYROSINE PHOSPHATASE INHIBITORS

Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

ESTROGEN RECEPTOR MODULATORS

The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, metastatic bone disease, Paget's disease, periodontal disease, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, inflammation, inflammatory bowel disease, sexual dysfunction, hypertension, retinal degeneration and cancer, in particular of the breast, uterus and prostate.

ESTROGEN RECEPTOR MODULATORS

The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, metastatic bone disease, Paget’s disease, periodontal disease, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, age-related mild cognitive impairment, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, inflammation, inflammatory bowel disease, irritable bowel syndrome, sexual dysfunction, hypertension, retinal degeneration and cancer, in particular of the breast, uterus and prostate.

Synthesis and preliminary pharmacological evaluation of trans-2-amino-5(6)-chloro-6(5)-hydroxy-1-phenyl-2,3-dihydro-1H-indenes as dopamine receptor ligands

A series of trans-2-amino-5(6)-chloro-6(5)-hydroxy-1-phenyl-2,3-dihydro-1H-indenes were synthesized and evaluated for their binding affinity toward D1-like and D2-like dopamine (DA) receptors. The affinity and selectivity of these compounds were measured in a test involving displacement of [3H]SCH 23390 or [3H]YM-09-151-2, respectively, from homogenates of porcine striatal membranes. All tested compounds were poorly effective at DA receptors (Ki nM>1000). The results suggest that introduction of chlorine substituent in five or six position of previously synthesized trans-2-amino-6(5)-hydroxy-1-phenyl-2,3-dihydro-1H-indenes decreases both D1-like and D2-like receptor affinity. Copyright